Loading patent…
AssigneeThe University of British Columbia
InventorsMartin E. Gleave, Palma Rocchi, Maxim Signaevsky, Eliana Beraldi
Estimating the term…
Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.
1-24. (canceled)
A pharmaceutical composition comprising a therapeutic agent effective to reduce the amount of active hsp27 in cancerous cells exposed to the therapeutic agent, and a pharmaceutically acceptable carrier, wherein the therapeutic agent is an antisense oligonucleotide having a sequence complementary to SEQ. ID NO. 91, wherein the oligonucleotide comprises at least ten bases complementary to bases 744-764 of SEQ. ID NO. 91, and wherein the antisense oligonucleotide is 12 to 35 nucleotides in length.
A pharmaceutical composition comprising a
Dependencies are inferred from the claim text.